Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $145.00 short put and a strike $135.00 long put offers a potential 8.7% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $145.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $9.20 would be incurred if the stock dropped below the $135.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 70.75 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
The Cold, Hard Barriers to Getting Vaccinated
Sun, 20 Dec 2020 22:00:20 +0000
(Bloomberg Opinion) â€” Doctors, nurses and other essential workers are getting vaccinated againstÂ Covid-19 in the U.S. and U.K.Â Yet in Asia, where severalÂ countriesÂ led the way in reining in the viral outbreak, there are few signs that detailedÂ distribution plans are ready to be implemented. Supplies areÂ limitedÂ and unknowns plentiful. Governments need to jump-start the process to get shots into arms.Â In most cases, however, their capacityÂ to distribute the vaccine is a constraint or simply doesnâ€™t exist.Some nations have signed on to procurement and advanced purchasing plans from vaccine manufacturers. Others are working on collaborations and homegrown options. But everywhere, the need to maintain optimal temperaturesÂ for certainÂ vaccines raises hardÂ issues,Â such asÂ cold-storage warehouses and adequate last-mile delivery.Â McKinsey & Co. has said that just 1% of existingÂ vaccine distribution networks isÂ set up for cold-chain requirements that keep the new Covid-19 serums viable â€” temperatures at the frozen or deep frozen(4) levels. Most low- and middle-income countries canâ€™t afford the infrastructureÂ investmentÂ in a short period. Many may have to borrow from multilateral organizations like the World Bank. That means limited funding and one shot at getting it right.So howÂ do governmentsÂ in their second,Â third or even fourth waves prepare? Most are using immunization plans fromÂ previous vaccine rollouts. TheseÂ wereÂ typically targeted at pregnant women and children, which are not the populations at the topÂ of the list in this pandemic. Indiaâ€™s universal immunization programÂ covers 26 million infants and 29 million mothers annually and isÂ the largest of its kind in the world. Yet experts sayÂ it wonâ€™t be sufficient.Andrea Taylor of Duke Universityâ€™s Global Health Institute says distribution plans will be based on four scenarios, rooted in refrigeration temperatures. Most mid-income and poorer countries have ruled out vaccines that need deep freezing, she says, and are preparing for the standard refrigeration scenario. Eventually, heat-stable vaccines and nasal spray formats could be the way.Â Â None of this is easy, but vaccine rollouts have always been more problematic in non-wealthyÂ countries. Almost two decades after the hepatitis B vaccine came out, the population coveredÂ was estimated at around 90% in the AmericasÂ and just 28% in Southeast Asia, where the disease isÂ a far larger problem.South Koreaâ€™s concurrentÂ experience with a campaign to inoculate 30 million people against influenzaÂ shows that thereâ€™sÂ always room for error, even in countriesÂ with well-established plans. The government recalled more than 1 million doses, to be on the safe side, afterÂ photos circulated onlineÂ of boxes of vaccinesÂ stacked in parking lots.Â Health authorities said that they found no direct causal links between the flu vaccine and the deaths ofÂ more thanÂ 100 peopleÂ who died after getting it. But the panic means that only 19 million people have so far takenÂ the shots. Singapore suspended its use.South Korea wasÂ an early global model for tracking, tracing and testing the rapid spread of Covid-19, but itâ€™s facing another surge in cases. Prime Minster Chung Sye-kyun saysÂ authorities willÂ come up with a plan allowing pre-purchased vaccines to be acquired in the first quarter of 2021; the country has said itâ€™s in the process of securing doses from companies including AstraZeneca Plc, Moderna Inc., Pfizer Inc. and Johnson & Johnsonâ€™s Janssen Pharmaceuticals Inc.Â But theÂ health ministerÂ has said thereâ€™s no hurry â€œwhen the risksÂ have not been verified yet.â€Thatâ€™s a fair concern. However, Covid-19 doesnâ€™tÂ allow the luxury of timeÂ of theÂ typical manufacturing supply chain.Â â€œWe cannot afford a sequential process,â€ David Simchi-Levi, director of the MIT Data Science Lab,Â told Supply Chain Dive.Â â€œWe need to start the manufacturing capacity today, and the problem is it requires significant investment.â€Then thereâ€™sÂ the more mundane but crucialÂ matter of trade facilitation: how to get vaccines across national borders.Â Think of this as the software of trade â€“ approvals, customs, tariffs, rules and regulations on inspection services, certification, permissions, how packages are handled, andÂ the intellectual property rules. AnÂ Asian Development Bank studyÂ in 2017 found that getting itÂ right increases immunization rates, especially in low-income countries.A look at the trade of medicines, totaling almost $50 billion globally, shows why the processÂ isnâ€™t so straightforward. Some regulations seem absurd in a time of global pandemic. For instance, the average applied tariff for hand soap is 17%, while some World Trade Organization members put it asÂ high as 65%. The average tariff on protective supplies isÂ 11.5%.In May,Â Canada invested more thanÂ $40 million to upgrade a vaccine production facility in Montreal â€œto ensure readiness for Canadian bioprocessing of potential vaccine candidates as they become available.â€ It was supposed to produce 250,000 doses by November. ThenÂ a partnership with Chinaâ€™s CanSino Biologics Inc.Â fell apart because Chinese customs authorities held up the first shipment of trial doses to Canada.Without a timely and straightforward way to get aÂ vaccine, Covid-19 wonâ€™t be eradicated. And the economic recovery that we see signs ofÂ wonâ€™t really take off.(1) Frozen: -15to -25 degrees celsius. Deep frozen: -60 to -80 degrees celsius.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Anjani Trivedi is a Bloomberg Opinion columnist covering industrial companies in Asia. She previously worked for the Wall Street Journal. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.Â©2020 Bloomberg L.P.
3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now
Sun, 20 Dec 2020 11:09:00 +0000
There are also a few stocks of the companies making these vaccines that are unparalleled in some ways. Here are three extraordinary coronavirus vaccine stocks that you can buy right now. Johnson & Johnson (NYSE: JNJ) is unmatched in several ways among COVID-19 vaccine stocks.
2 COVID Vaccine Stocks With Key Results on the Way
Sat, 19 Dec 2020 12:07:00 +0000
Corrine Cardina: My last topic for us before we try to tackle a couple of Slido questions is turning to the companies that are next in line to cross this finish line, what do we know about the timeline for Johnson & Johnson (NYSE: JNJ) and AstraZeneca’s (NASDAQ: AZN) phase 3 data? Johnson & Johnson has kept their information a little closer to the vest than a lot of these companies.
5 Top Stocks You Can Buy Now and Hold Forever
Sat, 19 Dec 2020 12:07:00 +0000
It’s easy to buy a stock, but to hold it through market crashes requires immense willpower and patience. For example, did you know Waste Management (NYSE: WM) stock could have more than quadrupled your money in just the past decade? The company offers resilient business and steady dividend growth, both of which are here to stay for decades to come.
J&J (JNJ) Coronavirus Vaccine Candidate Study Fully Enrolled
Fri, 18 Dec 2020 18:52:06 +0000
Johnson & Johnson (JNJ) phase III study on its experimental COVID-19 single-dose vaccine candidate is now fully enrolled.
Follow Us on Facebook